# Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression

> **NCT01282632** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 42 (actual)

## Conditions studied

- Subjects Had Unipolar, Non-psychotic Major Depression

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT01282632
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282632, "Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01282632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*